|Articles|December 14, 2022
Understanding the true cost of transparency reporting
Author(s)PwC
When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
